AstraZeneca presents advances in oncology research at ECC 2015 with data on AZD9291, durvalumab and LYNPARZA™ (olaparib)
AstraZeneca, along with MedImmune, the company’s global biologics research and development arm, will illustrate the strength and depth of research underpinning its scientific leadership...
New England Journal of Medicine publishes results of head-to-head studies of brodalumab versus ustekinumab in psoriasis
The New England Journal of Medicine (NEJM) has published positive results from two pivotal, multi-centre, Phase III studies –AMAGINE-2 and AMAGINE-3 – demonstrating that...
AstraZeneca receives Complete Response Letter from US FDA for saxagliptin / dapagliflozin fixed-dose-combination
AstraZeneca today announced that the US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the New Drug Application (NDA)...
AstraZeneca and Lilly expand immuno-oncology research collaboration with new combinations
AstraZeneca and Eli Lilly and Company (Lilly) today announced an extension to their existing immuno-oncology collaboration exploring novel combination therapies for the treatment of...
FDA Advisory Committee recommends the approval of lesinurad for gout patients
AstraZeneca today announced that the US Food and Drug Administration’s (FDA) Arthritis Advisory Committee (AAC) voted 10 to 4 to recommend the approval of...
Genentech’s Ocrelizumab First Investigational Medicine to Show Positive Pivotal Study Results in Both Relapsing and Primary Progressive Forms of Multiple Sclerosis
Genentech, a member of the Roche group announced data from three positive, pivotal Phase III studies of ocrelizumab in people with relapsing multiple sclerosis...
BioCryst Announces Completion of Patient Enrollment in OPuS-2: a Clinical Trial of Avoralstat in Patients With HAE
BioCryst Pharmaceuticals, Inc., (NASDAQ:BCRX) today announced that it has completed enrollment in OPuS-2 (Oral ProphylaxiS-2), a blinded, randomized, placebo-controlled clinical trial of orally-administered avoralstat...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...